Cantor Fitzgerald adjusted its outlook on Informatica (NYSE:INFA) shares by lowering the price target to $18.00 from the ...

Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...

CVS Health (CVS) stock was upgraded by Cantor Fitzgerald to Overweight after the company posted strong Q4 results earlier in ...

It’s not that the Trump administration is anti-Goldman Sachs, sources say, but rather there just isn’t as much talent to take ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Axsome Therapeutics in a note issued ...

Cantor Fitzgerald Investment Advisors L.P. decreased its stake in shares of Meta Platforms, Inc. (NASDAQ:META – Free Report) by 1.6% in the fourth quarter, according to its most recent 13F filing with ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is confident that Cigna can correct their stop-loss pricing ...

In a report released yesterday, Matthew Prisco from Cantor Fitzgerald maintained a Buy rating on Onto Innovation (ONTO – Research Report), with ...